Trial Profile

A Phase 2b study evaluating the dose, safety, and efficacy of PA5108 in Open-angle-glaucoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Latanoprost (Primary)
Indications Ocular hypertension; Open-angle glaucoma
Focus Therapeutic Use

Most Recent Events

06 Nov 2025 According to PolyActiva media release, company announced that the Phase 2b U.S. trial is currently underway in approximately 75 patients across 12 sites to evaluate PA5108.
06 Aug 2025 According to PolyActiva media release, company announced that the first U.S. patient has been enrolled in this Phase 2b clinical trial evaluating PA5108
06 Aug 2025 Status changed from planning to recruiting, According to PolyActiva media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com